InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report) fell 1.6% during mid-day trading on Monday . The stock traded as low as C$4.13 and last traded at C$4.19. 17,035 shares were traded during trading, a decline of 42% from the average session volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Down 1.6 %
The stock’s 50 day moving average is C$4.19. The stock has a market cap of C$33.73 million and a PE ratio of -2.77. The company has a current ratio of 2.13, a quick ratio of 1.45 and a debt-to-equity ratio of 8.48.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
Further Reading
- Five stocks we like better than InMed Pharmaceuticals
- How to Invest in the FAANG Stocks
- Survey: Top 175 Fittest Retirement Locations in America
- Find and Profitably Trade Stocks at 52-Week Lows
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.